Search Our Scientific Publications & Authors

Bioorg Med Chem 2022 May 10;66:116810. Epub 2022 May 10.

Institute of Medical Technology, Peking University Health Science Center, Beijing 100191, China; Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China; NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Beijing 100142, China. Electronic address:

Prostate-specific membrane antigen (PSMA) is emerging as a promising target to specifically image prostate cancer. Dual-modality probe combining radionuclide imaging and near-infrared fluorescence navigation targeting PSMA would enable both the preoperative staging and intraoperative detection of the tumor lesions. To overcome one of the key barriers for achieving high contrast imaging at both early and late time points, we optimized the pharmacokinetics of dual-modality probes based on oxalyldiaminopropionic acid-urea (ODAP-Urea) PSMA inhibitors recently developed. Read More

Mol Biol Evol 2022 May;39(5)

Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT, USA.

Mutational processes in tumors create distinctive patterns of mutations, composed of neutral "passenger" mutations and oncogenic drivers that have quantifiable effects on the proliferation and survival of cancer cell lineages. Increases in proliferation and survival are mediated by natural selection, which can be quantified by comparing the frequency at which we detect substitutions to the frequency at which we expect to detect substitutions assuming neutrality. Most of the variants detectable with whole-exome sequencing in tumors are neutral or nearly neutral in effect, and thus the processes generating the majority of mutations may not be the primary sources of the tumorigenic mutations. Read More

Int J Cancer 2022 May 17. Epub 2022 May 17.

Department of Public Health and Health Policy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Previous studies had limited power to assess the associations of testosterone with aggressive disease as a primary endpoint. Further, the association of genetically predicted testosterone with aggressive disease is not known. We investigated the associations of calculated free and measured total testosterone and sex hormone-binding globulin (SHBG) with aggressive, overall and early-onset prostate cancer. Read More

J Pathol 2022 May 17. Epub 2022 May 17.

Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.

Lung diseases carry a significant burden of morbidity and mortality worldwide. The advent of digital pathology (DP) and an increase in computational power have led to the development of artificial intelligence (AI) based tools that can assist pathologists and pulmonologists in improving clinical workflow and patient management. While previous works have explored the advances in computational approaches for breast, prostate, and head and neck cancers, there has been a growing interest in applying these technologies to lung diseases as well. Read More

Technol Cancer Res Treat 2022 Jan-Dec;21:15330338221100231

Department of Radiation Oncology, 6429Stanford University, Stanford, CA, USA.

The first clinical biology-guided radiation therapy (BgRT) system-RefleXion X1-was installed and commissioned for clinical use at our institution. This study aimed at evaluating the treatment plan quality and delivery efficiency for IMRT/SBRT cases without PET guidance. A total of 42 patient plans across 6 cancer sites (conventionally fractionated lung, head, and neck, anus, prostate, brain, and lung SBRT) planned with the Eclipse treatment planning system (TPS) and treated with either a TrueBeam or Trilogy were selected for this retrospective study. Read More